KR950031108A - 백신으로서 정제된 분류가능하지 않은 헤모필루스 인플루엔자 p5 단백질, 및 그의 정제 방법 - Google Patents
백신으로서 정제된 분류가능하지 않은 헤모필루스 인플루엔자 p5 단백질, 및 그의 정제 방법 Download PDFInfo
- Publication number
- KR950031108A KR950031108A KR1019950011163A KR19950011163A KR950031108A KR 950031108 A KR950031108 A KR 950031108A KR 1019950011163 A KR1019950011163 A KR 1019950011163A KR 19950011163 A KR19950011163 A KR 19950011163A KR 950031108 A KR950031108 A KR 950031108A
- Authority
- KR
- South Korea
- Prior art keywords
- protein
- epitopes
- haemophilus influenza
- epitope
- peptide
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract 8
- 229960005486 vaccine Drugs 0.000 title claims abstract 7
- 241000606768 Haemophilus influenzae Species 0.000 title claims 11
- 238000000746 purification Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 6
- 101710116435 Outer membrane protein Proteins 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 230000000844 anti-bacterial effect Effects 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 3
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 claims 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 claims 2
- 206010061876 Obstruction Diseases 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 238000005341 cation exchange Methods 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108700004121 sarkosyl Proteins 0.000 claims 2
- 229940117986 sulfobetaine Drugs 0.000 claims 2
- 206010001076 Acute sinusitis Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 101710091045 Envelope protein Proteins 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 108700022034 Opsonin Proteins Proteins 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 101710188315 Protein X Proteins 0.000 claims 1
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 208000022760 infectious otitis media Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000001662 opsonic effect Effects 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 241000606790 Haemophilus Species 0.000 abstract 1
- 206010061190 Haemophilus infection Diseases 0.000 abstract 1
- 238000000164 protein isolation Methods 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/807—Hapten conjugated with peptide or protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
본 발명은 헤모필루스 세균의 P5 외막 단백질 또는 P5 단백질에 대한 항체에 관한 것이다. 또한 본 발명은 P5 단백질 단리 방법 및 헤모필루스 인플루엔자 감염치료에 사용하기 위한 백신 조성물에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 정제된 분류가능하지 않은 (non-typable)P5 단백질 및 유형 B P5 단백질의 나트륨 도데실 설페이트(SDS)겔을 제공한다. 레인 1의 이중선은 P5 단백질의 열변형 및 비-열변형 형태를 나타낸다. 제2도는 항균 항체를 유도할 수 있는 정제된 P5 단백질의 아미노산 서열을 제공한다. 제3도는 NTHi P5에 대한 토끼 항혈청으로부터 발생된 전세포 엘리사(Elisa)종말점 역가를 제공한다.
Claims (14)
- 살균 항체를 유도하는, 헤모필루스 인플루엔자 균주의 실질적으로 순수한 P5외막 단백질 또는 그의 에피토프 또는 에피토프들을 갖는 그의 펩티드
- 제1항에 있어서, 에피토프가 분류가능하지 않은 헤모필루스 인플루엔자의 본질적으로 모든 균주의 외막상에 존재하는 펩티드 또는 단백질.
- 제1항에 있어서, 아미노산 서열에 제2도에 제공된 P5 단백질 또는 아미노산 잔기가 숙주에서 헤로필루스 인플루엔자에 대해 살균 항체를 유도하는 단백질의 살균 성질 또는 옵소닌 성질 또는 둘다가 손상되지 않으면서 추가, 삽입, 치환 또는 결실된 임의로 변형된 서열.
- 제3항의 단백질의 에피토프 또는 에피토프들 또는 에피토프들의 조합물에 대한 아미노산 서열에서 상응하는 올리고뉴클레오티드로서, 분류가능하지 않은 헤모필루스 인플루엔자에 대항해 항체 또는 항체들을 유도할 수 있는 유리 또는 접합 형태의 올리고뉴클FP오티드.
- N-라우로일 사르코신, 나트륨 염 수용액으로써, 외막 단백질의 화합물 제제를 추출한 후에 헤모필루스 인플루엔자의 외막으로부터 P5단백질을 단리 및 정제하는 방법으로서, 하기(a)-(e)로 구성됨을 개선점으로 하는 방법 : (a) 설포베타인 수용액으로써 P5단백질을 함유하는 불융성 잔기를 추출하는 단계 ; (b)N-라우로일-사르코시네이트로써 단계(a)의 불용성 잔기를 용해시키는 단계 ; (c) 설포베타인으로써 단계(b)의 잔기를 투석시키는 단계; (d)적당한 양이온 교환 컬럼으로부터 P5단백질을 용출시키는 단계 ; (e) 용출후에 양이온 교환 컬럼으로부터 본질적으로 순수한 P5 단백질을 회수하는 단계.
- 제약학적으로 허용가능한 부형제 및 임의 보조약내의; 면역원 양의헤모필루스 인플루엔자 P5단백질 또는 그의 에피토프 또는 에피토프들을 갖는 펩티드로 구성되는 백신 조성물.
- 제6항에 있어서, 최소한 1개의 부가적 항원 또는 하나 이상의 유기체를 더 포함하는 백신 조성물.
- 제7항에 있어서, 유기체가 세균, 비루스, 기생충 또는 곰팡이인 백신 조성물.
- 제약학적으로 허용가능한 부형제 및 임의 보조약내에 유기체의 항원 또는 그의 에피토프 또는 에피토프들의 항원에 접합된 P5 단백질 또는 그의 에피토프 또는 에피토프들을 갖는 펩티드로 구성되는 항원 접합물로 이루어진 백신 조성물.
- 제9항에 있어서, 유기체는 헤모필루스 인플루엔자인 백신 조성물.
- 면역원량의 헤모필루스 인플루엔자 P5단백질 또는 그의 에피토프 또는 에피토프들을 갖는 펩티드를 개체에게 투여하는 것으로 구성되는, 헤모필루스 인플루엔자에 대항해 면역화시키는 방법.
- 제11항에 있어서, P5단백질은 제2도에 도시된 아미노산 서열 또는 아미노산 잔기가 단백질의 살균 성질 또는 옵소닌 성질 또는 둘다가 본질적으로 손상되지 않으면서 추가, 삽입, 치환 또는 결실된 그의 임의의로 변형된 서열을 갖는 방법.
- 제12항에 있어서, P5단백질 또는 그의 에피토프 또는 에피토프들을 갖는 펩티드를 최소한 하나의 헤모필루스 인플루엔자의 다른 항원과 함께 투어하는 방법.
- 면역원량의 헤모필루스 인플루엔자 P5 단백질 또는 중이염, 부비강염 또는 만성 폐 차단 질병으로부터 유래된 그의 에피토프 또는 에피토프들을 갖는 펩티드를 개체에게 투여하는 것으로 구성되는, 급성 중이염, 부비강염 또는 만성 폐 차단 질병에 걸릴 가능성을 감소시키거나 예방하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/210,394 US5770213A (en) | 1994-05-05 | 1994-05-05 | Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection |
| US08/210394 | 1994-05-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR950031108A true KR950031108A (ko) | 1995-12-18 |
| KR100366482B1 KR100366482B1 (ko) | 2003-08-02 |
Family
ID=22782738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950011163A KR100366482B1 (ko) | 1994-05-05 | 1995-05-04 | 백신으로서 정제된 분류가능하지 않은 헤모필루스 인프루엔자 p5단백질, 및 그의 정제방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US5770213A (ko) |
| EP (1) | EP0680765B1 (ko) |
| JP (2) | JP4236215B2 (ko) |
| KR (1) | KR100366482B1 (ko) |
| AT (1) | ATE356633T1 (ko) |
| AU (1) | AU704882B2 (ko) |
| CA (1) | CA2148563C (ko) |
| DE (1) | DE69535422T2 (ko) |
| DK (1) | DK0680765T3 (ko) |
| ES (1) | ES2282992T3 (ko) |
| FI (1) | FI120149B (ko) |
| IL (1) | IL113595A (ko) |
| NO (1) | NO951750L (ko) |
| PT (1) | PT680765E (ko) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002089839A1 (en) * | 2001-05-03 | 2002-11-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis |
| US20040126381A1 (en) * | 1996-04-23 | 2004-07-01 | Xin-Xing Gu | Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella |
| GB9812613D0 (en) * | 1998-06-11 | 1998-08-12 | Smithkline Beecham Biolog | Vaccine |
| US6974581B1 (en) * | 1998-12-15 | 2005-12-13 | Aventis Pasteur Limited | Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease |
| GB9904183D0 (en) * | 1999-02-24 | 1999-04-14 | Smithkline Beecham Biolog | Novel compounds |
| US7101989B1 (en) | 1999-07-09 | 2006-09-05 | University Of North Carolina At Chapel Hill | DsrA protein and polynucleotides encoding the same |
| GB0025486D0 (en) * | 2000-10-17 | 2000-11-29 | Smithkline Beecham Biolog | Novel compounds |
| WO2004009621A2 (en) * | 2002-07-24 | 2004-01-29 | Id Biomedical Corporation | Polypeptides of nontypeable haemophilus influenzae |
| IL308456A (en) | 2005-04-08 | 2024-01-01 | Wyeth Llc | A multivalent pneumomuroral protein-polysaccharide conjugate preparation |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| KR101854904B1 (ko) * | 2008-09-17 | 2018-06-20 | 헌터 이뮤놀로지 리미티드 | 비피막형 헤모필루스 인플루엔자 백신 및 그의 용도 |
| KR102409709B1 (ko) | 2021-11-30 | 2022-06-16 | 박정민 | 케이블 접속장치 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5300632A (en) * | 1986-11-18 | 1994-04-05 | Research Foundation Of State University Of New York | Method for purifying an outer membrane protein of Haemophilus influenzae |
| US5098997A (en) * | 1987-12-11 | 1992-03-24 | Praxis Biologics, Inc. | Vaccines for Haemophilus influenzae |
| US5098987A (en) * | 1989-07-13 | 1992-03-24 | The United States Of America As Represented By The Secretary Of The Air Force | Crosslinkable rigid-rod benzobisazole polymer |
| ATE226831T1 (de) | 1993-05-18 | 2002-11-15 | Univ Ohio State Res Found | Impfstoff gegen mittelohrentzündung |
-
1994
- 1994-05-05 US US08/210,394 patent/US5770213A/en not_active Ceased
-
1995
- 1995-05-02 EP EP95302996A patent/EP0680765B1/en not_active Expired - Lifetime
- 1995-05-02 DK DK95302996T patent/DK0680765T3/da active
- 1995-05-02 ES ES95302996T patent/ES2282992T3/es not_active Expired - Lifetime
- 1995-05-02 AT AT95302996T patent/ATE356633T1/de not_active IP Right Cessation
- 1995-05-02 DE DE69535422T patent/DE69535422T2/de not_active Expired - Lifetime
- 1995-05-02 JP JP13295495A patent/JP4236215B2/ja not_active Expired - Fee Related
- 1995-05-02 PT PT95302996T patent/PT680765E/pt unknown
- 1995-05-03 AU AU17814/95A patent/AU704882B2/en not_active Ceased
- 1995-05-03 IL IL11359595A patent/IL113595A/en not_active IP Right Cessation
- 1995-05-03 CA CA002148563A patent/CA2148563C/en not_active Expired - Fee Related
- 1995-05-04 FI FI952144A patent/FI120149B/fi active IP Right Grant
- 1995-05-04 KR KR1019950011163A patent/KR100366482B1/ko not_active IP Right Cessation
- 1995-05-04 NO NO951750A patent/NO951750L/no unknown
-
2000
- 2000-06-21 US US09/599,652 patent/USRE37741E1/en not_active Expired - Lifetime
-
2008
- 2008-10-24 JP JP2008274435A patent/JP2009051859A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL113595A (en) | 2001-05-20 |
| NO951750D0 (no) | 1995-05-04 |
| ATE356633T1 (de) | 2007-04-15 |
| DE69535422T2 (de) | 2007-12-13 |
| CA2148563A1 (en) | 1995-11-06 |
| FI120149B (fi) | 2009-07-15 |
| EP0680765B1 (en) | 2007-03-14 |
| DE69535422D1 (de) | 2007-04-26 |
| FI952144A0 (fi) | 1995-05-04 |
| US5770213A (en) | 1998-06-23 |
| NO951750L (no) | 1995-11-06 |
| ES2282992T3 (es) | 2007-10-16 |
| JP4236215B2 (ja) | 2009-03-11 |
| PT680765E (pt) | 2007-05-31 |
| IL113595A0 (en) | 1995-08-31 |
| FI952144A (fi) | 1995-11-06 |
| JPH08337598A (ja) | 1996-12-24 |
| AU704882B2 (en) | 1999-05-06 |
| USRE37741E1 (en) | 2002-06-11 |
| EP0680765A1 (en) | 1995-11-08 |
| KR100366482B1 (ko) | 2003-08-02 |
| CA2148563C (en) | 2008-10-07 |
| JP2009051859A (ja) | 2009-03-12 |
| AU1781495A (en) | 1995-11-16 |
| DK0680765T3 (da) | 2007-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Montaraz et al. | Identification of a 68-kilodalton protective protein antigen from Bordetella bronchiseptica | |
| KR100271888B1 (ko) | 모락셀라 카타랄리스의 유용한 항원과 관련된 방법 및 조성물 | |
| US7273611B1 (en) | Proteinase K resistant surface protein of neisseria meningitidis | |
| EP2241625A1 (en) | Proteinase K resistant surface protein of neisseria meningitidis | |
| Bakaletz et al. | Relative immunogenicity and efficacy of two synthetic chimeric peptides of fimbrin as vaccinogens against nasopharyngeal colonization by nontypeable Haemophilus influenzae in the chinchilla | |
| EP0453024B1 (en) | Actinobacillus pleuropneumoniae subunit vaccine | |
| KR950031108A (ko) | 백신으로서 정제된 분류가능하지 않은 헤모필루스 인플루엔자 p5 단백질, 및 그의 정제 방법 | |
| RU98101249A (ru) | Омр26 антиген haemophylus influenzae | |
| EA014531B1 (ru) | Антиамилоидные иммуногенные композиции, способы и применения | |
| JP2010083898A (ja) | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン | |
| RU2001134170A (ru) | Антигенные пептиды NEISSERIA | |
| Yi et al. | Importance of an immunodominant surface-exposed loop on outer membrane protein P2 of nontypeable Haemophilus influenzae | |
| JP4290875B2 (ja) | 組換え脂質化ＰｓａＡタンパク質、調製法および使用 | |
| AU621288B2 (en) | Vaccine against pasteurella | |
| Webb et al. | Immunization with recombinant transferrin binding protein B enhances clearance of nontypeable Haemophilus influenzae from the rat lung | |
| JP2762310B2 (ja) | ストレプトコッカルｍプロテイン由来の合成ペプタイド及び当該ペプタイドから調製されたワクチン | |
| RU2186582C2 (ru) | Способ выделения и очистки белка внешней мембраны moraxella catarrhalis, штамм м.catarrhalis для получения белка cd, изолированный и очищенный неденатурированный белок cd внешней мембраны м.catarrhalis и иммуногенная композиция, содержащая белок cd внешней мембраны м.сatarrhalis | |
| AU676140B2 (en) | Preparation of recombinant borrelia proteins | |
| JP4105393B2 (ja) | インフルエンザ菌由来の少なくとも２つの抗原を含む、疾病予防のための多成分ワクチン | |
| Poolman et al. | Purification, cyanogen bromide cleavage, and amino terminus sequencing of class 1 and class 3 outer membrane proteins of meningococci | |
| WO2004041182A2 (en) | M. haemolytica outer membrane protein plpe as a vaccine or vaccine component against shipping fever | |
| US7794734B2 (en) | Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever | |
| DK1146889T3 (da) | Identifikation af specifikke differentielt udtrykte mycobakterielle antigener og medicinsk anvendelse af Mycobakteriumproteinerne Rv0068 og Rv3407 | |
| Ayalew et al. | Characterization of Immunodominant and | |
| JPH0631319B2 (ja) | 緑膿菌感染に対してワクチン活性を有するリポ糖蛋白ｐｓｃ―ａおよび緑膿菌ワクチン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20101129 Year of fee payment: 9 |
|
| LAPS | Lapse due to unpaid annual fee |